FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia.

Saved in:
Bibliographic Details
Title: FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia.
Authors: Ondrisova L; Molecular Medicine, CEITEC Masaryk University, Brno, Czechia.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia., Seda V; Molecular Medicine, CEITEC Masaryk University, Brno, Czechia.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia., Hlavac K; Molecular Medicine, CEITEC Masaryk University, Brno, Czechia.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia., Pavelkova P; Molecular Medicine, CEITEC Masaryk University, Brno, Czechia.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia., Hoferkova E; Molecular Medicine, CEITEC Masaryk University, Brno, Czechia.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia., Chiodin G; Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom., Kostalova L; Molecular Medicine, CEITEC Masaryk University, Brno, Czechia.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia., Mladonicka Pavlasova G; Molecular Medicine, CEITEC Masaryk University, Brno, Czechia., Filip D; Molecular Medicine, CEITEC Masaryk University, Brno, Czechia.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia., Vecera J; Molecular Medicine, CEITEC Masaryk University, Brno, Czechia.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia., Zeni PF; Molecular Medicine, CEITEC Masaryk University, Brno, Czechia., Oppelt J; Molecular Medicine, CEITEC Masaryk University, Brno, Czechia., Kahounova Z; Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czechia., Vichova R; Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czechia., Soucek K; Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, Czechia., Panovska A; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia., Plevova K; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia., Pospisilova S; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia., Simkovic M; Fourth Department of Internal Medicine-Haematology, University Hospital Hradec Kralove and Faculty of Medicine Hradec Kralove, Charles University, Prague, Czechia., Vrbacky F; Fourth Department of Internal Medicine-Haematology, University Hospital Hradec Kralove and Faculty of Medicine Hradec Kralove, Charles University, Prague, Czechia., Lysak D; Department of Haematology and Oncology, University Hospital Pilsen, Pilsen, Czechia., Fernandes SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Maiques-Diaz A; Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain., Charalampopoulou S; Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain., Martin-Subero JI; Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain., Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Doubek M; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia., Forconi F; Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; Haematology Department, Cancer Care Directorate, University Hospital Southampton NHS Trust, Southampton, United Kingdom., Mayer J; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia., Mraz M; Molecular Medicine, CEITEC Masaryk University, Brno, Czechia.; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Source: The Journal of clinical investigation [J Clin Invest] 2024 Oct 22; Vol. 134 (23). Date of Electronic Publication: 2024 Oct 22.
Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-8238
DOI:10.1172/JCI173770